Thank you for the question. I'll answer quickly because I think you also wanted Mr. Ferri to jump in.
There are a couple of things.
First of all, I'll say that our position has always been that removing intellectual property barriers was one part of the solution. I think it has always been clear that removing the patent issue from the equation was never going to be entirely sufficient. We have always said that, in addition to this, there needs to be effective technology transfer to manufacturers in low- and middle-income countries. I think it is also clear that there is capacity in countries to produce vaccines if they have the legal right to do so and if the technology is transferred to them along with manufacturing know-how and so on.
I agree—and we said this in our statement as well—that we are in a different phase of the pandemic, where supply is no longer the predominant issue, but that's a relatively recent development. We also have always maintained that what countries needed was a stable, predictable supply of vaccines from the start.
We work in roughly 70 countries around the world, and we supplement and provide vaccination campaigns and activities in many low-income countries. We're familiar with the difficulties of running even basic vaccination campaigns in difficult circumstances. Under-resourced health systems were always going to have a difficult time scaling up vaccination campaigns, but the solution to that was to make vaccines available equitably and throughout the pandemic, so that countries had the ability to scale up their vaccination activities and be able to plan for them and roll them out.